tiprankstipranks
Novavax Comments on Expected U.S. Vaccine Market Outlook
Company Announcements

Novavax Comments on Expected U.S. Vaccine Market Outlook

Pick the best stocks and maximize your portfolio:

Novavax ( (NVAX) ) has provided an update.

Novavax, Inc. has acknowledged a recent analyst report discussing the expected U.S. COVID-19 vaccine market for the upcoming 2024-2025 season. The company clarified that although it predicts a market similar to the previous year, it has not changed or reconfirmed its financial guidance for the full year of 2024.

For an in-depth examination of NVAX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyNovavax says Australia cancels delivery of some Covid-19 doses
TheFlyUnusually active option classes on open December 16th
TheFlyNovavax advances growth strategy through partnership with Sanofi
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App